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Abstract
Introduction Timing of cord clamping and other cord
management strategies may improve outcomes at preterm
birth. However, it is unclear whether benefits apply to all
preterm subgroups. Previous and current trials compare
various policies, including time-based or physiology-based
deferred cord clamping, and cord milking. Individual
participant data (IPD) enable exploration of different
strategies within subgroups. Network meta-analysis
(NMA) enables comparison and ranking of all available
interventions using a combination of direct and indirect
comparisons.
Objectives (1) To evaluate the effectiveness of cord
management strategies for preterm infants on neonatal
mortality and morbidity overall and for different participant
characteristics using IPD meta-analysis. (2) To evaluate
and rank the effect of different cord management
strategies for preterm births on mortality and other key
outcomes using NMA.
Methods and analysis Systematic searches of Medline,
Embase, clinical trial registries, and other sources for
all ongoing and completed randomised controlled trials
comparing cord management strategies at preterm birth
(before 37 weeks’ gestation) have been completed up
to 13 February 2019, but will be updated regularly to
include additional trials. IPD will be sought for all trials;
aggregate summary data will be included where IPD are
unavailable. First, deferred clamping and cord milking will
be compared with immediate clamping in pairwise IPD
meta-analyses. The primary outcome will be death prior to
hospital discharge. Effect differences will be explored for
prespecified participant subgroups. Second, all identified
cord management strategies will be compared and
ranked in an IPD NMA for the primary outcome and the
key secondary outcomes. Treatment effect differences by
participant characteristics will be identified. Inconsistency
and heterogeneity will be explored.
Ethics and dissemination Ethics approval for this
project has been granted by the University of Sydney

Strengths and limitations of this study
►► This will be the most comprehensive review to date

of interventions for umbilical cord management in
preterm infants and the findings will be highly relevant to clinicians and guideline developers.
►► The use of individual participant data will allow assessment of the best treatment option for key subgroups of participants.
►► Network meta-analysis will enable the comparison
and ranking of all available treatment options using
direct and indirect evidence.
►► For some of the trials it will not be possible to obtain
individual participant data, so published aggregate
results will be used instead.
►► Risk of bias in the primary trials will be assessed
using Cochrane criteria, and certainty of evidence
for the meta-analyses will be appraised using the
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) approach for the pairwise comparisons, and the CINeMA (Confidence in
Network Meta-Analysis) approach for the network
meta-analysis.
Human Research Ethics Committee (2018/886). Results
will be relevant to clinicians, guideline developers and
policy-makers, and will be disseminated via publications,
presentations and media releases.
Registration number Australian New Zealand Clinical
Trials Registry (ANZCTR) (ACTRN12619001305112) and
International Prospective Register of Systematic Reviews
(PROSPERO, CRD42019136640).

Introduction
Currently over 15 million babies are born
preterm annually and this number is rising.1–3
Of these, 1.1 million die, and the morbidity
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‘physiological cord clamping’ which defers clamping until
after the onset of breathing. Yet, onset of breathing is not
always easy to determine without the assistance of video
or extra equipment, while timing to cord clamping can
be easily measured. In an earlier study,31 time of onset of
breathing in preterm infants receiving gentle stimulation
was related to time after birth—within a minute over 90%
of preterm infants had begun spontaneous breathing.
Cord milking or stripping (pinching the umbilical cord
close to the mother and moving the fingers towards the
infant) may be a way to increase preterm blood volume
without deferring clamping.32 Yet, a preterm lamb model
demonstrated that during cord milking there was a transient increase of carotid blood flow and pressure.33 A
recent trial comparing deferred cord clamping with cord
milking was stopped early in the subgroup of extremely
preterm infants (23–27 weeks), as the incidence of severe
intraventricular haemorrhage was higher in the cord
milking group.34 Hence, the effect of cord milking in
different populations needs further elucidation.

Current approaches to cord clamping
One potential mechanism of deferring umbilical cord
clamping is a net transfer of blood from the placenta to
the baby known as ‘placental transfusion’. If the cord is
not clamped at birth immediately, blood flow between the
placenta and the baby may continue for up to 5 min in term
infants.11–13 For preterm births, blood flow may continue
for longer,14 since a greater proportion of fetoplacental
circulating blood volume is still in the placenta.15 This has
led to time-based approaches to deferring cord clamping
that have been shown to increase peak haematocrit and
reduce the need for blood transfusions.16 Yet, recent findings suggest that placental transfusion does not always
occur—blood flow may continue without any net transfer,
and sometimes net transfer may be to the placenta.17
Initial neonatal care and stabilisation traditionally takes
place on a resuscitation platform at the side of the room
or in an adjacent room. Deferred cord clamping is thus
often associated with a delay in neonatal care and this has
led to concerns including delayed resuscitation and hypothermia18 particularly for very preterm infants and infants
assessed as requiring resuscitation. An alternate emerging
strategy is to provide immediate neonatal care with the
cord intact beside the woman using a mobile resuscitation trolley or on the mother’s leg.19–23
Another potential mechanism of deferred clamping
is allowing time for the infant to establish spontaneous
breathing while still placentally supported. Immediate
cord clamping before the infant has established breathing
may be harmful since it can lead to large fluctuations in
blood pressure, a period of hypoxia and restricted cardiac
function.24 Animal and pilot human studies suggest
that breathing and lung aeration before cord clamping
can improve cardiovascular stability and oxygenation,
and reduce intraventricular haemorrhage and infant
mortality.25–28 They also suggest that initial respiratory
support before clamping the cord can improve cerebral oxygenation and blood pressure, and reduce cerebrovascular impairment compared with immediate
cord clamping.29 30 This evidence has led to the rise of

Current guidelines for cord management at birth and previous
reviews of aggregate data
Current uncertainties in optimal cord management
strategies are reflected in varying guidelines. The WHO
recommends late cord clamping35 unless resuscitation is required, the National Institute for Health and
Care Excellence (NICE) recommends waiting for 30 s
to 3 min if mother and baby are stable,36 and the International Liaison Committee on Resuscitation Council
(ILCOR) recommends a delay in cord clamping of at
least 1 min. If the baby is assessed as requiring resuscitation (which is the case in many preterm infants),37 WHO
recommends immediate clamping,38 NICE recommends
considering cord milking before clamping and ILCOR
concludes that there is insufficient evidence to make any
recommendations.37
A 2012 Cochrane review of timing of cord clamping for
preterm births39 included 15 trials, with 738 infants, of
which one trial (with 40 infants) compared cord milking
with immediate cord clamping.32 There was heterogeneity in the timing of cord clamping and gestational age
at recruitment, and data were insufficient for reliable
conclusions about any of the primary outcomes of the
review. A systematic review and meta-analysis published in
2018 (including 18 trials with 2834 infants) compared the
effect of deferred (≥30 s) versus early (<30 s) clamping in
preterm infants, and found a reduction in the primary
outcome of hospital mortality by 32% (risk ratio=0.68,
95% CI 0.52 to 0.90).16 There was heterogeneity in the
definition of ‘early cord clamping’ ranging from less than
5 s to 25 s, and ‘late cord clamping’, ranging from 30 s to
180 s. Recruitment age varied from 22 weeks to 36 weeks'
gestational age. Most analyses of infant and maternal
morbidity were substantially underpowered.16 The review
concluded that while there is high quality evidence that
deferred cord clamping improves outcomes, individual
participant data (IPD) analyses are urgently needed to
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and healthcare costs among survivors and their families
are high, with preterm survivors having an increased risk
of cognitive, developmental and behavioural difficulties,
and chronic ill health.4–9 Hence, even modest improvements in outcomes of preterm birth would substantially
benefit the children, their families and also health services.
In uncompromised babies, deferring cord clamping has
been shown to be beneficial and is now used in routine
practice.10 However, it is unclear whether these benefits
apply to preterm babies who usually receive immediate
neonatal care, and whether any benefits outweigh potential harms. In addition, there are multiple competing
cord management strategies, such as clamping the cord
at different times or milking the cord, and considerations of the infant’s respiratory status, and it is currently
unknown which strategy yields the best balance of benefits and harms.

Open access

Objectives
The aims of this study are:
1. To evaluate the effectiveness of cord management
strategies for preterm infants on neonatal mortality
and morbidity, and to evaluate patient-level modifiers
of treatment effect.
2. To evaluate, compare and rank the effectiveness of different cord management strategies for preterm infants
on mortality and the key secondary outcomes intraventricular haemorrhage (any grade) and infant blood
transfusions (any).

for reporting (PRISMA-Protocols (PRISMA-P) checklist
provided in online supplementary file 2).
Eligibility criteria
Types of studies
Studies will be included if they are randomised trials.
randomised and quasi-
random studies will be
Cluster-
excluded. Studies must compare at least two of the interventions of interest (defined below).
Trial participants
Participants will be women giving birth preterm (before
37 completed weeks’ gestation) and/or their babies. Individually randomised studies will be eligible for inclusion
if the unit of randomisation was either the woman, or the
baby. Women and babies will be included regardless of
whether mode of delivery was vaginal or caesarean, and
whether the birth was singleton or multiple. Correlations
between multiples will be accounted for in the analyses.
Babies will be included regardless of whether or not they
received immediate resuscitation at birth.
Types of interventions and comparators in pairwise meta-analysis
For the pairwise meta-analysis we will include all trials
that compare an intervention to enhance umbilical
blood flow or allow more time for physiological transition to the comparator immediate cord clamping. This
includes interventions assessing cord management strategies for timing of cord clamping, and other strategies
such as cord milking. Trials will be included regardless of
whether initial neonatal care is provided with the umbilical cord intact, or not. Different strategies (ie, deferred
cord clamping and cord milking) will be analysed in
separate subgroups to assess comparability between the
groups by assessing subgroup effects and heterogeneity.
They will then be collapsed into one ‘cord management
intervention’ group if they are deemed comparable based
on the previous subgroup assessments. If they are deemed
non-comparable they will be analysed and interpreted
separately.

Methods and analysis
We will conduct a systematic review of randomised trials
with IPD using pairwise meta-analysis and NMA, and a
nested prospective meta-analysis. The lead investigator
for all potentially eligible studies will be contacted and
invited to collaborate and join the IPD Cord Management
at Preterm birth (iCOMP) Collaboration. Eligible trials
identified up to February 2019 are listed in online supplementary file 1. The Collaboration will undertake this
project according to the methods recommended by the
Cochrane IPD, Multiple Interventions, and Prospective
Meta-Analysis Methods Groups.40 45 46 Reporting guidelines for NMA protocols by Chaimani et al47 and Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) extension for protocols48 49 have been followed

Types of interventions and comparators in NMA
For the NMA we will include, as interventions of interest,
strategies for timing of cord clamping, and other cord
management strategies to influence umbilical flow and
placental transfusion.
Thus, interventions of interest include:
►► Immediate cord clamping without milking (≤15 s or
trialist defined).
►► Short deferral of cord clamping (>15 s to <45 s)
without milking.
►► Medium deferral of cord clamping (≥45 to <90 s)
without milking.
►► Long deferral of cord clamping (≥90 s) without
milking.
►► Cord milking or stripping before immediate cord
clamping (intact cord milking).
►► Cord milking or stripping before deferred cord
clamping (intact cord milking).

Seidler AL, et al. BMJ Open 2020;10:e034595. doi:10.1136/bmjopen-2019-034595
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further understand the benefits and potential harms of
different cord management strategies, and to understand
whether differential treatment options are advantageous
for key subgroups of infants.16
This ongoing uncertainty about the optimal cord
management strategy, and differential cord management
strategies for key subgroups of infants (eg, for those
for which resuscitation and/or stabilisation is deemed
necessary, or extremely preterm infants) has led to 117
planned, ongoing or published trials (in more than
15 000 preterm babies) that are comparing a range of
cord management strategies. IPD meta-analysis is the gold
standard for combining such trial data. IPD provides
larger statistical power for estimation of treatment
effects of rarer secondary endpoints and enables reliable
subgroup analyses to examine hypotheses about differences in treatment effect, exploring interactions between
treatment-
level and participant-
level characteristics.40
Network meta-analysis (NMA) facilitates data synthesis when
there is a range of interventions available and permits
indirect comparisons across all interventions by inferring
the relative effectiveness of two competing treatments
through a common comparator.41 42 NMA produces relative effect estimates for each intervention compared with
every other intervention in the network. These effect sizes
can be used to obtain rankings of the effectiveness of the
interventions.43 Using IPD in NMA (as opposed to aggregate data) can improve precision, increase information
and reduce bias.44

Open access

Network of possible comparisons between cord management interventions.

Cord milking or stripping after immediate cord
clamping (cut cord milking).
►► Cord milking or stripping after deferred cord
clamping (cut cord milking).
►► Physiological clamping (clamping after aeration of
lungs).
If we identify other interventions not listed above we will
include them if they are addressing cord management or
related strategies to influence umbilical flow and placental
transfusion. Again, trials will be included regardless of
whether initial neonatal care is provided with the umbilical
cord intact, or not. Studies evaluating collection and storage
of residual placental blood that is then used for transfusion after birth will be excluded. All possible comparisons
between eligible interventions are displayed in figure 1. For
interpretation purposes, immediate cord clamping will act
as the basis comparison/parameter.
Nodes that specify different timings of cord clamping
were defined according to what timing is classified as
immediate clamping, short deferral, medium deferral or
long deferral according to the literature to date (as shown
in online supplementary file 1), and after discussion with
clinicians. Different timings are commonly compared in
head-to-head comparisons, hence, their classification as
different intervention nodes. Similarly, nodes that specify
cord milking were classified after a review of current
milking techniques described in the literature and after
discussion with clinicians. If insufficient data are available,
categories will be collapsed where possible. For instance,
milking before and after immediate cord clamping could
be collapsed into one single immediate cord milking

category, or medium and long delay could be collapsed
into a medium to long delay category. We consider the
interventions of interest to be jointly randomisable (ie,
each participant could, in principle, be randomised to
any one of the interventions of interest).
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►►

Types of outcome measures
Trials must report at least one of the clinical outcomes
included in this review, as specified in the “measures”
section below, to be included.
Eligibility for nested prospective meta-analysis
Studies are only included in the nested prospective meta-
analysis if the investigator/s were blind to outcome data
by intervention group at the time the main components
of the protocol (ie, objectives, aims and hypotheses, eligibility criteria, subgroup and sensitivity analyses, and main
outcomes) were initially agreed in January 2015.
Information sources and search strategy
The search strategy to identify potentially eligible studies
includes a search of the Cochrane Collaboration Pregnancy and Childbirth Review Group’s Trial Register. This
register contains trials identified from: monthly searches
of the Cochrane Central Register of Controlled Trials
(CENTRAL) and CINAHL (EBSCO); weekly searches
of Medline (Ovid) and Embase (Ovid); hand searches
of specialty journals and major conferences proceedings; and current awareness alerts from further journals and BioMed Central. Further details can be found
elsewhere.50 We will identify ongoing trials that may be

BMJ Open: first published as 10.1136/bmjopen-2019-034595 on 29 March 2020. Downloaded from http://bmjopen.bmj.com/ on July 23, 2020 by guest. Protected by copyright.

Figure 1
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Selection of studies for inclusion in the review
Two members of the iCOMP Secretariat (see project
management section below) will independently assess all
the potentially eligible studies identified for inclusion.
Disagreements will be resolved by discussion or, if required,
by consulting a third member of the iCOMP Secretariat.
Studies that are not willing or able to provide IPD will be
synthesised where possible using aggregate data.
Data collection, management and confidentiality
Data receipt
Each participating trial will be asked to provide deidentified, individual participant-level data. Clear instructions
will be provided on which data are needed and the secure
data transfer process. The preferred data format and
coding for each variable will be supplied to the investigators, but data in any format that is most convenient will
be accepted and recoded if necessary. Data management
will comply with the University of Sydney Data Management Policy 2014. Depending on trialists’ preference,
data transfer will either take place via secure data transfer
platforms, or will be shared via institutional secure email
using password-protected zip files. Data for this project
will be stored in perpetuity in a password-
protected
folder within the NHMRC (National Health and Medical
Research Council) Clinical Trials Centre’s network. Only
authorised project team members working within the
NHMRC Clinical Trials Centre will have access to these
data.
Data processing
Data checking: For each trial, range and internal consistency of all variables will be checked. Intervention details
and missing data will be checked against any protocols,
published reports and data collection sheets. Integrity
of the randomisation process will be assessed by examining the chronological randomisation sequence and
the balance of participant characteristics across intervention groups. Any inconsistencies or missing data will
be discussed with the trialists and resolved by consensus.
Each included study will be analysed separately and the
results sent to the trial investigators for verification prior
specific
to inclusion in the iCOMP database. All trial-
Seidler AL, et al. BMJ Open 2020;10:e034595. doi:10.1136/bmjopen-2019-034595

outcomes generated from the IPD will be cross-checked
against published information via a series of crosstabs.
Data recoding: Outcome data may have been collected
in different formats across trials. Therefore, the deidentified data from each of the trials will be extracted and
reformatted into a commonly coded data set.
Data transformation and collating: Once the data from
each of the trials are finalised, they will be combined into
a single data set, but a trial identifier code for each participant will be retained. New variables will be generated
from the combined data set as required to address the
hypotheses to be tested.
Risk of bias assessment and certainty of evidence appraisal
Eligible studies will be assessed for risk of bias using the
criteria described in the Cochrane Handbook:51 random
sequence generation; allocation concealment; blinding
of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and
other bias. Uncertainties will be resolved where possible
by contacting study authors. Certainty of evidence will
be appraised using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach52 for the pairwise comparisons, and the rating
approach suggested by Salanti et al that is implemented
in the Confidence in Network Meta-Analysis (CINeMA)
application for the NMA.53
Outcomes measures for pairwise meta-analysis
All outcome measures for the pairwise meta-analysis are
listed in table 1. The primary outcome will be death of
the baby prior to hospital discharge. As outcomes for
babies born very preterm (before 32 weeks’ gestation)
are different to those born moderately preterm (32–37
weeks), separate analyses will be conducted for these two
groups of infants for the secondary outcomes. Where
possible, definitions will be standardised, otherwise
outcomes will be used as defined in individual trials.
Secondary outcomes will include measures of neonatal
and maternal morbidity, and health service use.
Covariates and subgroups for pairwise meta-analysis
Subgroup analyses will be conducted for the primary
outcome of death (prior to hospital discharge) and two
key secondary outcomes (intraventricular haemorrhage
any grade and any infant blood transfusion). All included
covariates and subgroups are listed in table 1. The comparative effects of alternative cord management strategies may
vary depending on key infant risk factors, and/or on the
level and type of neonatal care available at the hospital
of birth. Thus, there will be subgroup analyses based on
participant-level characteristics and based on hospital-level
characteristics. If data are insufficient for the prespecified
subgroup analyses, categories will be collapsed.
Data analysis for pairwise meta-analysis
The full Statistical Analysis Plan will be agreed on by the
iCOMP Collaboration before any analyses are undertaken. Analyses will include all randomised participants
5
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eligible by searching for published protocols in Medline
and Embase, searching online registries of clinical trials,
and personal contacts (for example, by asking collaborators to notify any unregistered studies they are aware of).
The Chief Investigators of eligible trials will be invited to
join the iCOMP Collaboration. They will also be asked if
they know of any further planned, ongoing or completed
studies. Databases will be searched from their inception. Preliminary searches using this search strategy have
already been completed up to 13 February 2019, but the
search will be updated regularly to include additional
trials. The search strategy is outlined in more detail in
online supplementary file 3.

Open access

Outcomes
For all infants
Primary outcome

Death prior to hospital discharge

For infants born before 32 weeks’ gestation
Key secondary outcomes

►► Death (at any time during follow-up)
►► Severe intraventricular haemorrhage on cranial ultrasound (grade 3–4)
►► All grades of intraventricular haemorrhage on cranial ultrasound
►► Necrotising enterocolitis ≥grade 2 (or trialist definition)
►► Late-onset sepsis (where possible defined as clinical sepsis >72 hours after birth)
►► Patent ductus arteriosus requiring treatment (medical and/or surgical)
►► Chronic lung disease (at 36 weeks’ postmenstrual age or trialist defined)
►► Blood transfusion (yes/no)

Other secondary outcomes

►► Death (within 7 days)
►► Other forms of white matter brain injury (eg, periventricular leukomalacia, porencephaly)
►► Respiratory support (mechanical ventilation, CPAP, low nasal flow oxygen)
►► Duration of respiratory support
►► Supplemental oxygen at 36 weeks
►► Retinopathy of prematurity requiring treatment (medical and/or surgical)
►► Drug treatment for hypotension (yes/no)
►► Blood transfusion (number, volume)
►► Hypothermia on admission to neonatal unit
►► Haemoglobin
►► Haematocrit
►► Polycythaemia
►► Jaundice requiring treatment
►► Birth weight
►► Length of stay in NICU/SCU
►► Length of stay in hospital
►► Apgar scores at 1 min and 5 min
►► Long-term developmental disability (assessed using the Bayley III, and/or other tools):
–– Cerebral palsy
–– Neurodevelopmental disability
–– Score on cognitive scale
–– Score on language scale
–– Score on social/emotional scale
–– Score on motor scale
–– Score on behaviour scale
–– Deafness
–– Blindness

For infants born at or after 32 weeks’ gestation
Key secondary outcomes

►► Death at any time (during follow-up)
►► Admission to NICU
►► Blood transfusion (any, number, volume)

Other secondary outcomes

►► Death (within 7 days)
►► Haemoglobin
►► Haematocrit
►► Jaundice requiring treatment
►► Length of stay in NICU/SCU
►► Length of stay in hospital
►► Duration of respiratory support (mechanical ventilation, CPAP, low flow nasal oxygen)
►► Chronic lung disease
►► Late-onset sepsis (>72 hours after birth)
►► Patent ductus arteriosus requiring treatment (medical and/or surgical)
►► Drug treatment for hypotension
►► Hypothermia on admission to neonatal unit or postnatal ward
►► Apgar score at 1 min and 5 min
►► Long-term developmental disability (assessed using the Bayley III, and/or other tools):
–– Cerebral palsy
–– Neurodevelopmental disability
–– Score on cognitive scale
–– Score on language scale
–– Score on social/emotional scale
–– Score on motor scale
–– Score on behaviour scale
–– Deafness
–– Blindness

Continued
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Table 1 Measures for individual participant data pairwise meta-analysis
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Outcomes
For all women
Secondary outcomes

►► Maternal death
►► Postpartum haemorrhage
►► Postpartum sepsis requiring treatment
►► Manual removal of placenta
►► Retained placenta
►► Not breastfeeding when baby discharged from hospital
►► Postnatal depression
►► Blood transfusion

Covariates/subgroups
Participant-level characteristics
 

►► Gestation at birth
►► Type of pregnancy: singleton; multiple
►► Maternal age
►► Mode of birth: caesarean before onset of labour; caesarean after onset of labour; vaginal
►► Onset of labour: spontaneous onset or spontaneous prelabour ruptured membranes; not spontaneous
onset or spontaneous prelabour ruptured membranes; not known whether spontaneous onset of labour or
spontaneous prelabour ruptured membranes
►► Type of breathing onset: spontaneous breathing onset; supported lung aeration (ventilation); unknown
►► Time of breathing onset relative to cord clamping: before cord clamping/milking; after cord clamping/milking;
unknown
►► Sex (male, female, uncertain/other)
►► Ethnicity (trialist defined)
►► Small for gestational age (trialist defined): yes/no
►► Maternal antenatal/intrapartum/postpartum sepsis requiring treatment (trialist defined): yes/no
►► Assessed as needing resuscitation and/or stabilisation (yes/no)
►► Type of uterotonic drug (if any)

Hospital/trial-level characteristics
 

►► Highest level of neonatal unit available at site: NICU, neonatal unit (some capacity to provide ventilation),
special care baby unit (no ventilation available), no neonatal unit or special care baby unit
►► Planned timing of uterotonic drug: before cord clamping; after/at cord clamping; timing mixed or not known
►► Planned position of the baby relative to the placenta while cord intact: level with placenta (between level of
woman’s bed and her abdomen/anterior thigh); more than 20 cm below level of placenta; position mixed or
not known
►► Need for immediate resuscitation at birth: infants requiring immediate resuscitation at birth excluded; infants
requiring immediate resuscitation at birth included; unclear whether infants requiring immediate resuscitation
at birth included or excluded
►► Type of consent: waiver of consent; deferred consent; informed consent or assent; type of consent unclear
►► Study year

CPAP, continuous positive airway pressure; NICU, neonatal intensive care unit; SCU, special care unit.

for which data are available, and the primary analyses will
be based on intention-to-treat. Analyses will be conducted
using the open-source software R.54
For each outcome, a one-stage approach to analysis
will be employed to include IPD from all eligible trials
in a multilevel random-effects or mixed-effects regression model. Aggregate data will be included where
IPD are unavailable.55 Relative heterogeneity of treatment effects across trials will be estimated using I2, with
further inclusion in secondary models of participant-
level and trial-level covariates to explain the sources of
heterogeneity. Prediction intervals will be estimated to
ascertain absolute heterogeneity. Forest plots will be
presented by trial for the primary outcome, and for any
secondary outcomes where there is evidence of heterogeneity across trials.
We will use a generalised linear modelling framework,
with the choice of outcome distribution and link function dependent on outcome type. For example, binomial
Seidler AL, et al. BMJ Open 2020;10:e034595. doi:10.1136/bmjopen-2019-034595

with log link will be used to estimate risk ratios for binary
outcomes, and Gaussian with identity link for mean differences, with log-transformation of the data if appropriate.
We will follow a similar approach for secondary outcomes.
For estimation of subgroup effects, we will present forest
plots of pooled treatment effects according to prespecified subgroup variables, and estimate effects by including
appropriate interaction terms between a subgroup variable and treatment arm in the regression models. The
results of all comparative analyses will be presented using
appropriate estimates of treatment effect along with 95%
CIs and two-sided p values.
Outcome measures for NMA
The primary outcome for the NMA will be death of the
baby during the initial hospital stay. If data availability
permits, IVH (any grade) and blood transfusion (any)
will be analysed as two key secondary outcomes.
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Table 1 Continued

Open access

Assessment of the transitivity assumption for NMA
Transitivity in the network will be assured by only including
interventions that are regarded as jointly randomisable and
by limiting our sample to preterm infants. Gestational age
at birth, hospital setting (highest level of available neonatal
care), as well as study year may act as effect modifiers and
could influence the transitivity of the network. We will
therefore investigate whether these variables are distributed
evenly across comparisons. If we find any of those variables
to be unevenly distributed, they will be included in the
network as covariates to investigate their influence on the
network and on possible inconsistency.

Assessment of inconsistency for NMA
Global consistency will be assessed using the Q statistics
for inconsistency and the design-by-treatment interaction
model. Local consistency will be assessed using the loop-
specific approach and the node-
splitting approach to
explore sources of inconsistency. Since tests of inconsistency are known to have low power, results will be interpreted with caution, and potential known sources for
inconsistency will be explored even if there is no statistical
evidence of inconsistency. Any detected inconsistency will
be explored by including covariates specified above (gestational age at birth, hospital setting, as well as study year)
into the model, and by excluding potential outlier studies
in sensitivity analyses. In case of a judgement of excessive
heterogeneity or inconsistency we would still report the
resulting parameters, but would interpret the results as not
reliable.
Assessment of compliance with the allocated intervention
Compliance with the interventions will be described
for each trial. For studies of early versus deferred cord
clamping this will be based on (1) The time to cord
clamping in each allocated group. (2) The difference in
time between early and deferred clamping. For studies
comparing cord milking with no milking, this will be
based on (1) Time to cord clamping in the allocated
groups. (2) Reported compliance with cord milking in
both groups.

Data analysis for NMA
analysis, all analyses will be
As for the pairwise meta-
specified a priori in a full Statistical Analysis Plan, all
randomised participants for which data are available will
be included, and the primary analyses will be intention-
to-treat. Again, aggregate data will be included where IPD
are unavailable.
We will calculate a two-step random-effects contrast-
based network meta-regression to compare and rank all
available interventions for the primary outcome death
(during initial hospital stay) and for the two key secondary
outcomes—IVH (any grade) and blood transfusion (any).
Summary risk ratios with CIs and prediction intervals will
be presented for each pairwise comparison in a league
table. We will estimate the ranking probability of each
intervention being at each rank, and we will use surface
under the cumulative ranking curve and mean ranks to
obtain a treatment hierarchy. A frequentist approach
to analysis will be used. Should models not converge, a
Bayesian approach will be used instead, setting a weakly
informative prior d ∼ N (0, 5). Correlations induced by
multiarm studies will be accounted for using multivariate
distributions.
As a second step, interactions between key covariates
and effect estimates will be tested, assuming a common
interaction across comparisons. If there are statistically
significant interactions between covariates and treatment effects, we will provide probability rankings of
intervention effects by subgroup for these covariates. A
single heterogeneity parameter will be assumed for each
network. Statistical heterogeneity will be assessed using
the I2 statistic.

Adjustments for multiplicity
There is only one primary outcome, and few key
secondary outcomes for this study. For other secondary
outcomes, no formal adjustments for multiplicity (ie, the
accumulation of type 1 error and thus higher likelihood
of chance findings when assessing multiple outcomes)
are planned. Instead, we will be taking the following
approach outlined by Schulz and Grimes:57 as secondary
outcomes examined in this study are interrelated, we will
interpret the pattern of results, examining consistency of
results across related outcomes, instead of focusing on
any single, statistically significant result. All secondary
outcomes will be reported. Subgroup analyses will be
performed by testing for interactions and findings will be
reported as exploratory.58
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Assessment of selection bias
We will perform a nested prospective meta-
analysis
as a sensitivity analysis, to detect potential differences
between prospectively and retrospectively included
studies that may point to selection or publication bias.
We expect to also be able to include some unreported
outcomes sourced from the IPD provided by the included
studies, which may alleviate selective outcome reporting
bias.40 Additionally, comparison-
adjusted and contour-
enhanced funnel plots56 will be used to examine whether
there are differences in results between more and less
precise studies.

BMJ Open: first published as 10.1136/bmjopen-2019-034595 on 29 March 2020. Downloaded from http://bmjopen.bmj.com/ on July 23, 2020 by guest. Protected by copyright.

Covariates and subgroups for NMA
Subgroup analyses will be conducted for the primary
outcome (death before discharge) and the two key
secondary outcomes (IVH any grade, blood transfusion).
Gestational week at birth and highest level of available
care will be considered as effect modifiers to improve
consistency of the NMA model. There will be subgroup
analyses assessing treatment effect by week of gestational
age, and by comparing babies assessed as in need of
immediate resuscitation versus not in need of immediate
resuscitation.

Open access

Project management
The iCOMP Collaboration will invite membership from
representatives of each of the included trials contributing

Figure 2

IPD, have a Secretariat, and invite methodological
and clinical experts who will form an Advisory Group.
The Secretariat will be responsible for data collection,
management and analysis, and for communication within
the Collaboration.
Public and patient involvement
Two consumer representatives have been invited to join
the iCOMP collaboration, comment on this protocol and
be involved in the interpretation of results.
Ethical issues
For each included trial, ethics approval has been previously granted by their respective Human Research Ethics
Committees (or equivalent), and informed consent has
been obtained from all participants. The Chief Investigators of the included trials remain the custodians of their
own trial’s data. IPD from the included trials will be deidentified before sharing with the iCOMP Collaboration.
Publication policy
The key methods for this meta-
analysis protocol were
agreed by the iCOMP Collaborators in January 2015,
before unblinding of any outcome data from the studies
included in the nested prospective meta-analysis. This
manuscript was discussed at the iCOMP Collaborators’
meeting held at the Paediatric Academic Societies meeting
in San Diego in April 2015. At this meeting it was agreed
the protocol should be expanded to include a retrospective systematic review and IPD and NMA with a nested
prospective meta-analysis. The protocol was then revised,
based on further discussion, and circulated to members

Illustration of network of currently available trials comparing different timings of cord clamping.
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Planned sensitivity analyses
To assess whether results are robust to trial characteristics
and methods of analysis, the following sensitivity analyses
will be conducted for the primary outcome, if data are
sufficient:
►► Excluding trials with high risk of bias for sequence
generation and/or concealment of allocation and/or
loss to follow-up for pairwise meta-analysis and NMA.
►► Excluding trials with a significant conflict of interest
(eg, trials funded by pharmaceutical companies).
►► For trials comparing early cord clamping with
deferred clamping, analysis of outcomes weighted by
degree of separation in mean actual timing of cord
clamping between intervention and control groups
for pairwise meta-analysis.
►► Analysis of outcomes weighted by degree of separation in haemoglobin (at 24 hours) achieved between
intervention and control groups for pairwise meta-
analysis (as a surrogate for net placental transfusion).
►► For trials with deferred cord clamping, an additional
dose-
response analysis assessing intended time of
cord clamping deferral as a continuous variable will
be performed.
►► Exploratory analysis based on actual, rather than
intended, timing of cord clamping for individual
participants for pairwise meta-analysis and NMA.
►► The impact of missing data on the effects of the
included interventions for the primary outcome may
be explored (if appropriate).

Open access

Discussion
There is an urgency to conduct this systematic review
and pairwise IPD and NMA so we can make sense of the
numerous trials currently being undertaken, inform clinical practice and identify the most promising interventions for further evaluation.
This meta-analysis offers an opportunity to reliably test
important hypotheses that cannot be resolved by any of
the individual trials, either alone or in simple combination. Coordinating international efforts in this way will
help achieve consensus on the most important substantive clinical outcomes to assess in any future trials as
needed. Unequivocal synthesised results, together with
the identification of key determinants (eg, effect modifiers), will be critical for translating evidence from this
meta-analysis directly into practice. Figure 2 shows the
network of comparisons available from the trials identified to date. We plan to complete study identification
and IPD collection by early 2020, then conduct the analyses and disseminate results by mid-2021. Trials that are
ongoing and therefore unable to provide data by March
2020 will remain members of the iCOMP collaboration.
Their data will be included in future updates of iCOMP.
This study is only possible because trialists around
the world have agreed to collaborate to share the IPD
from their cord management trials. This collaborative
approach will enable us to move beyond the traditional
‘one-
size-
fits-
all’ and towards precision medicine, to
find the optimal intervention from a range of treatment
options for each individual woman and her baby, based
on their individual characteristics and risk factors.
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of the iCOMP Collaboration for further comment and
agreement prior to manuscript submission.
Participating trialists in the prospective meta-
analysis,
when reporting results from their own trials, will endeavour
to include a statement that their trial is part of this prospective meta-analysis in any published manuscripts or conference abstracts. Any reports of the results of this meta-analysis
will be published either in the name of the collaborative
group, or by representatives of the collaborative group on
behalf of the iCOMP Collaboration, as agreed by members
of the collaborative group. Draft reports will be circulated to
the collaborative group for comment and approval before
submission for publication.
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